摘要
对110例原发性高血压(EHT)患者和163例正常对照者取血测定其血管紧张素转换酶(ACE)基因I与 D多态性及循环中酶活性。高血压组D等位基因频率高于对照组,分别为 0.518 2和0.432 5(P<0.05)。两组中ACE活性均存在DD>ID>Ⅱ。高血压组及对照组ID型ACE活性分别为314.1±67.94和258.35±64.11(P<0.01),Ⅱ型分别为259.68±69.68和220.88±62.85(P<0.05)。高血压组应用赖诺普利后各基因型患者血压均有明显下降,降压幅度DD>ID>Ⅱ。结果显示ACE基因多态性与原发性高血压有密切关系,DD型有高易患性。ACE活性受基因型控制,DD型活性最高。应用赖诺普利后各基因型血压均有下降,降压幅度 DD> ID> Ⅱ。 DD型可作为ACE抑制剂应用的最佳指征。
The angiotensin-converting enzyme(ACE)gene I/D polymorphisms and serum enzyme activities were measured in 110 essential hypertension (EH) patients and 163 normal controls. Lisinopril was given to all EH patients for 12 weeks. D allele frequency of EH patients was higher than that of the normals, 0.521 8 and 0.432 5 respectively(P < 0.05 ). The ACE enzyme activities were found DD> ID> II. Enzyme activity of ID genotype was higher in EH patients than in normals, 314.1 ±67.94 and 258. 35± 64.11 respectively(P< 0.01 )and that of II genotypes was 259.68±69.68 and 220. 88 ± 62. 85 respectively(P < 0.05 ). Blood pressure, both SAP and DBP were decreased in all genotypes after the use of lisinopril, especially in DD genotype. In conclusion, I/D polymorphism of ACE gene was correlated with EH and controlled serum enzyme activity. DD genotype strongly indicated for use of ACE inhibitors.
出处
《天津医药》
CAS
1999年第6期329-332,共4页
Tianjin Medical Journal
关键词
高血压
赖诺普利
ACE基因多态性
EHT
药物疗法
peptidyl-dipeptidase A restriction fragment length polymorphism
immunocompetence hypertension lisinopril